Physician

David Mark King, M.D.

According to 2025 Medicare claims, David King, M.D. (NPI: 1417049396) practices medical oncology in the Minneapolis-St. Paul-Bloomington, MN-WI market, with the plurality of this provider's patient population coming from Anoka, MN. This provider's primary affiliated billing organization is MINNESOTA ONCOLOGY HEMATOLOGY, PA (NPI: 1528035995; TIN: 411793418) and primary practice location at 55432-2866. King is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

King's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 430 traditional Medicare patients, billed 167,175 HCPCS/CPT codes, and received $2,931,806 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 3,794 prescription claims across 427 beneficiaries totaling $4,306,167 in drug costs, led by Pomalyst (Pomalidomide). DME data shows 26 claims. Open Payments data shows 5 records totaling $46,875. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $572,197 to $2,931,806. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $2,250 and ending at $9,733.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	296	34,030	$572,197
2016	257	31,704	$533,369
2017	289	42,178	$660,595
2018	301	60,629	$1,116,176
2019	516	167,681	$2,836,638
2020	450	114,976	$1,777,107
2021	444	157,858	$2,175,683
2022	435	158,328	$2,335,296
2023	466	155,443	$2,703,578
2024	430	167,175	$2,931,806

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	335	3,376	$2,308,168
2016	311	3,267	$2,557,462
2017	315	3,253	$1,681,103
2018	349	3,648	$2,124,749
2019	359	3,242	$2,157,582
2020	337	3,096	$1,890,811
2021	334	2,744	$1,425,816
2022	377	3,139	$2,558,141
2023	419	3,631	$2,648,521
2024	427	3,794	$4,306,167

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	14	$967
2016	N/R	57	$1,439
2017	N/R	53	$14,833
2018	N/R	74	$2,569
2019	N/R	65	$6,503
2020	N/R	44	$1,720
2021	N/R	35	$785
2022	N/R	79	$4,889
2023	N/R	70	$6,581
2024	N/R	26	$1,307

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	210	407	$67
80053	Blood test, comprehensive group of blood chemicals	292	1,071	$10
36415	Insertion of needle into vein for collection of blood sample	244	714	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	282	1,150	$8
83615	Lactate dehydrogenase (enzyme) level	273	948	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	25	679	$555,285
Lenalidomide	Lenalidomide	40	1,120	$499,327
Ibrance	Palbociclib	29	812	$456,462
Calquence	Acalabrutinib Maleate	31	930	$405,045
Xtandi	Enzalutamide	26	780	$362,457

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
B4152	Enteral formula, nutritionally complete, calorically dense (equal to or greater than 1.5 kcal/ml) with intact nutrients, includes proteins, fats, carbohydrates, vitamins and minerals, may include fiber, administered through an enteral feeding tube, 100 calories = 1 unit	N	N/R	15	$724
B4034	Enteral feeding supply kit; syringe fed, per day, includes but not limited to feeding/flushing syringe, administration set tubing, dressings, tape	N	N/R	11	$583

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	0	$0	N/R
Research Payments	Reported research-related payment or transfer-of-value amount.	5	$46,875	Celgene Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for David Mark King, M.D.?

Tedicare shows public-source Medicare data for David Mark King, M.D. (NPI 1417049396), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David Mark King, M.D. have ACO affiliation data?

David Mark King, M.D. is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to David Mark King, M.D.?

David Mark King, M.D. is linked to MINNESOTA ONCOLOGY HEMATOLOGY, PA (billing NPI 1528035995) in the available physician profile data.

Does David Mark King, M.D. have Open Payments data?

David Mark King, M.D. has 5 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.